Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

261. First report of hepatitis E virus viremia in healthy blood donors from Nepal

First report of hepatitis E virus viremia in healthy blood donors from Nepal 28466048 2018 11 13 2347-3584 27 3 2016 Sep Virusdisease Virusdisease First report of hepatitis E virus viremia in healthy blood donors from Nepal. 324-326 10.1007/s13337-016-0331-y The aim of this study was to detect the prevalence of hepatitis E virus (HEV) in healthy blood donors so as to decipher the maintenance of (HEV) reservoir if any. Five hundred and eighty-one blood samples along with clinical information (...) were collected from central blood bank, Kathmandu between February and March 2014. Samples were tested for hepatitis B virus surface antigen, anti-hepatitis C virus antibodies, anti-hepatitis A virus IgM, HEV antigen, HEV viral load and anti-HEV antibodies (IgM and IgG) by ELISA. Only those samples positive with anti-HEV IgM were tested for HEV RNA by reverse transcriptase nested PCR. Age adjusted prevalence of IgM anti HEV and IgG anti HEV were 3.6 and 8.3 % respectively. No significant difference

Virusdisease2016 Full Text: Link to full Text with Trip Pro

262. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Background: Hepatitis C virus (HCV) infection is common in persons who inject drugs (PWID). Objective: To evaluate elbasvir-grazoprevir in treating HCV infection in PWID. Design: Randomized, placebo-controlled, double-blind trial. (ClinicalTrials.gov: NCT02105688 ). Setting: Australia, Canada, France, Germany, Israel, the Netherlands, New Zealand, Norway, Spain, Taiwan

Annals of Internal Medicine2016

263. NS5B and NS3 Inhibitors in Patients with Resistance-Associated Variants of Hepatitis C Virus: A Review of the Clinical Effectiveness

NS5B and NS3 Inhibitors in Patients with Resistance-Associated Variants of Hepatitis C Virus: A Review of the Clinical Effectiveness NS5B and NS3 Inhibitors in Patients with Resistance-Associated Variants of Hepatitis C Virus: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need NS5B and NS3 Inhibitors in Patients with Resistance-Associated Variants of Hepatitis C Virus: A Review of the Clinical Effectiveness NS5B and NS3 Inhibitors in Patients with Resistance (...) -Associated Variants of Hepatitis C Virus: A Review of the Clinical Effectiveness Published on: August 8, 2016 Project Number: RC0799-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of hepatitis C pharmacotherapies containing NS5B inhibitors in direct-acting antiviralnaive patients infected with NS5B resistance-associated variants of hepatitis C virus at baseline? What is the clinical effectiveness

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

264. Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort

Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort 29063026 2018 11 13 2095-882X 2 1 2016 Mar Chronic diseases and translational medicine Chronic Dis Transl Med Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort. 55-60 10.1016/j.cdtm.2016.07.001 Previous studies have revealed inconsistent results regarding the association between occult hepatitis B virus (HBV (...) ):232-44 16733348 Eur J Intern Med. 2011 Apr;22(2):161-6 21402246 Lab Invest. 1979 Oct;41(4):366-71 158675 Lancet. 2005 Jan 22-28;365(9456):331-40 15664230 Nephron Clin Pract. 2011;118(3):c269-77 21212690 Ann Intern Med. 2009 May 5;150(9):604-12 19414839 J Hepatol. 2005 Nov;43(5):764-70 16087273 Kidney Int. 2015 May;87(5):1030-8 25426815 Am J Kidney Dis. 2010 Jul;56(1):23-31 20400217 Nephrol Dial Transplant. 2013 Mar;28(3):641-51 23197682 Liver Int. 2015 Jan;35(1):148-55 24502506 Kidney Int. 2013

Chronic diseases and translational medicine2016 Full Text: Link to full Text with Trip Pro

265. Frequency of nucleotide sequence variations in the internal ribosome entry site region of hepatitis C virus RNA isolated from responding and non-responding patients with hepatitis C virus genotype 3 infection

Frequency of nucleotide sequence variations in the internal ribosome entry site region of hepatitis C virus RNA isolated from responding and non-responding patients with hepatitis C virus genotype 3 infection 28466036 2018 11 13 2347-3584 27 3 2016 Sep Virusdisease Virusdisease Frequency of nucleotide sequence variations in the internal ribosome entry site region of hepatitis C virus RNA isolated from responding and non-responding patients with hepatitis C virus genotype 3 infection. 251-259 (...) . 2000 Dec;32(6):1386-95 11093746 J Viral Hepat. 2006 Feb;13(2):87-95 16436126 J Gen Virol. 1998 Jun;79 ( Pt 6):1373-81 9634077 Hepatology. 1994 Jun;19(6):1513-20 8188183 J Gastroenterol Hepatol. 2004 May;19(5):551-7 15086599 Nucleic Acids Res. 2007;35(16):5409-21 17698501 Indian J Med Microbiol. 2013 Oct-Dec;31(4):354-9 24064641 Hepatitis C virus genotype 3 Internal ribosome entry site Nucleotide sequence variations Pegylated interferon-alpha Ribavirin 2016 03 22 2016 07 27 2017 5 4 6 0 2017 5 4 6 0

Virusdisease2016 Full Text: Link to full Text with Trip Pro

266. Anti-hepatitis, antioxidant activities and bioactive compounds of Dracocephalum heterophyllum extracts

Anti-hepatitis, antioxidant activities and bioactive compounds of Dracocephalum heterophyllum extracts 28597426 2018 11 13 1817-406X 57 1 2016 Dec Botanical studies Bot Stud Anti-hepatitis, antioxidant activities and bioactive compounds of Dracocephalum heterophyllum extracts. 16 10.1186/s40529-016-0133-y Dracocephalum heterophyllum was a traditional Tibetan medicine possesses various pharmacological effects involved in anti-inflammatory, antibacterial activities. However, its anti-hepatitis (...) , antioxidant activity and bioactive compounds have not been reported, the objective of this research work was to investigate the pharmacological activity and bioactive compounds of D. heterophyllum extracts. In the present study, the anti-hepatics and antioxidant activities of four D. heterophyllum extracts (i.e. petroleum ether extracts, ethyl acetate extracts, n-BuOH extracts, and water extracts) were conducted. The main chemical constituent of petroleum ether and ethyl acetate extracts were also

Botanical studies2016 Full Text: Link to full Text with Trip Pro

267. Management of hepatitis C, time for hope?

Management of hepatitis C, time for hope? Vol 23. DTB: Vol 23, No 4 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DTB: Vol 23, No 4 DTB: Vol 23, No 4 Content tools Share it Management of hepatitis C, time for hope? A management approach is proposed for HCV treatment. The situation is promising as newer drugs provide a clear improvement in efficacy. However, the clinical trial evidence has some limitations. These include a lack of head

Drug and Therapeutics Bulletin of Navarre (Spain)2016

268. Epclusa (sofosbuvir and velpatasvir) - To treat all six major forms of hepatitis C virus

Epclusa (sofosbuvir and velpatasvir) - To treat all six major forms of hepatitis C virus Epclusa Tablet U.S. Department of Health and Human Services Search FDA Submit search Epclusa Tablet Epclusa Company: Gilead Sciences, Inc. Application No.: 208341 Approval Date: 06/28/2016 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

FDA - Drug Approval Package2016

270. Supplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus–Associated Type 2 Diabetes: A Mini Review

Supplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus–Associated Type 2 Diabetes: A Mini Review 27777890 2018 11 13 2225-0719 4 3 2016 Sep 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Supplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus-Associated Type 2 Diabetes: A Mini Review. 228-233 Hepatitis C virus (HCV) infection and type 2 diabetes mellitus (T2DM) present a significant health burden (...) and cardiovascular disease. Ezzikouri Sayeh S Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco. Jadid Fatima Zahra FZ Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco. Hamdi Salsabil S Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco. Wakrim Lahcen L Virology Unit, Immunovirology Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco. Tsukiyama-Kohara Kyoko K Laboratory of Animal Hygiene

Journal of clinical and translational hepatology2016 Full Text: Link to full Text with Trip Pro

271. Re-treatment for Patients with NS5A Resistant-Associated Variants of Hepatitis C Virus: A Review of Clinical Effectiveness

Re-treatment for Patients with NS5A Resistant-Associated Variants of Hepatitis C Virus: A Review of Clinical Effectiveness Re-treatment for Patients with NS5A Resistant-Associated Variants of Hepatitis C Virus: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Re-treatment for Patients with NS5A Resistant-Associated Variants of Hepatitis C Virus: A Review of Clinical Effectiveness Re-treatment for Patients with NS5A Resistant-Associated Variants of Hepatitis C Virus (...) : A Review of Clinical Effectiveness Published on: July 28, 2016 Project Number: RC0798-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of re-treatment in patients with NS5A resistance-associated variants of hepatitis C virus who have failed on treatment with NS5A inhibitors? Key Message One low quality study9 showed that 12 weeks therapy with a combination regimen of sofosbuvir (SOF) and simeprevir (SIM

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

272. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.

Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The prison setting presents not only challenges, but also opportunities, for the prevention and treatment of HIV, viral hepatitis, and tuberculosis. We did a comprehensive literature search of data published between 2005 and 2015 to understand the global epidemiology of HIV, hepatitis C virus (HCV), hepatitis B virus (HBV), and tuberculosis in prisoners. We further modelled the contribution of imprisonment

Lancet2016

273. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.

The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Despite global reductions in HIV incidence and mortality, the 15 UNAIDS-designated countries of Eastern Europe and Central Asia (EECA) that gained independence from the Soviet Union in 1991 constitute the only region where both continue to rise. HIV transmission in EECA is fuelled primarily by injection of opioids, with harsh (...) criminalisation of drug use that has resulted in extraordinarily high levels of incarceration. Consequently, people who inject drugs, including those with HIV, hepatitis C virus, and tuberculosis, are concentrated within prisons. Evidence-based primary and secondary prevention of HIV using opioid agonist therapies such as methadone and buprenorphine is available in prisons in only a handful of EECA countries (methadone or buprenorphine in five countries and needle and syringe programmes in three countries

Lancet2016

274. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners.

Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. The prevalence of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis are higher in prisons than in the general population in most countries worldwide. Prisons have emerged as a risk environment for these infections to be further concentrated, amplified, and then transmitted to the community after prisoners are released. In the absence of alternatives to incarceration, prisons

Lancet2016

275. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis.

Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. The burden of HIV/AIDS and other transmissible diseases is higher in prison and jail settings than in the non-incarcerated communities that surround them. In this comprehensive review, we discuss available literature on the topic of clinical management of people infected with HIV, hepatitis B and C viruses, and tuberculosis in incarcerated settings in addition to co-occurrence of one or more of these infections

Lancet2016

276. Prevalence and Impact of Hepatitis on the Quality of Life of Patients

Prevalence and Impact of Hepatitis on the Quality of Life of Patients 29201700 2018 11 13 2231-5047 5 2 2015 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Prevalence and Impact of Hepatitis on the Quality of Life of Patients. 90-94 10.5005/jp-journals-10018-1142 Hepatitis is a disorder which is emerging as major health problem with increasing morbidity and mortality. Inappropriate management of this disease leads to several complications that can impair (...) the health related quality of life (HRQoL) of the individuals. There, we designed this study to assess the HRQoL in patients suffering from hepatitis. This prospective, observational study was conducted for 2 months in patients with hepatitis. All patients with hepatitis were recruited in the study after giving written informed consent. The participants were given both World Health Organization Quality of Life-Bref (WHO QoL-Bref) and short form (SF-36) health survey questionnaires for assessing

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

277. Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey

Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey 29201701 2018 11 13 2231-5047 5 2 2015 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey. 95-97 10.5005/jp-journals-10018-1143 Hepatitis A virus (HAV) can cause significant pathology in patients with chronic hepatitis B virus (HBV), however, HAV can be prevented (...) by vaccination. The aim of this study was to determine the implication of vaccination against HAV vaccine in patients with chronic hepatitis B. The seroprevalence of anti-HAV IgG antibodies was investigated in the patients with chronic hepatitis B. Anti-HAV IgG antibodies were detected by commercially available ELISA kit. A total of 673 patients (354 males, 319 females with age range of 17-78 years) with chronic hepatitis B were included the study. Hepatitis A virus seropositivity rate was 34

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

278. Autoimmune Hepatitis with Distal Renal Tubular Acidosis and Small Bowel Partial Malrotation

Autoimmune Hepatitis with Distal Renal Tubular Acidosis and Small Bowel Partial Malrotation 29201703 2018 11 13 2231-5047 5 2 2015 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Autoimmune Hepatitis with Distal Renal Tubular Acidosis and Small Bowel Partial Malrotation. 107-109 10.5005/jp-journals-10018-1145 Renal tubular acidosis (RTA) is not uncommon in patient with chronic autoimmune hepatitis (AIH), but usually remains latent. Here, we report a case (...) hepatitis should not be ruled out in each case of RTA presenting with jaundice. Modi TK, Parikh H, Sadalge A, Gupte A, Bhatt P, Shukla A. Autoimmune Hepatitis with Distal Renal Tubular Acidosis and Small Bowel Partial Malrotation. Euroasian J Hepato-Gastroenterol 2015;5(2):107-109. Kanaiyalal Modi Tejas T Department of Gastroenterology, Seth GS Medical College, KEM Hospital, Mumbai, Maharashtra, India. Parikh Hardik H Department of Gastroenterology, Seth GS Medical College, KEM Hospital, Mumbai

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

279. Hepatitis B Virus Reactivation under Treatment with Nilotinib

Hepatitis B Virus Reactivation under Treatment with Nilotinib 29201705 2018 11 13 2231-5047 5 2 2015 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Hepatitis B Virus Reactivation under Treatment with Nilotinib. 112-114 10.5005/jp-journals-10018-1147 Hepatitis B virus (HBV) reactivation with imatinib, a tyrosine kinase inhibitor, has been reported in chronic myeloid leukemia. Nilotinib is a more potent second generation tyrosine kinase inhibitor (...) assessment of hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc antibody) and antibody to hepatitis B surface antigen (anti-HBs), especially at countries with intermediate and high prevalence of HBsAg is warranted. Treatment with nucleoside analogs and close monitoring may be life-saving in this context. Temel T, Gunduz E, Sadigova E, Teke HU, Ozgenel SM, Ozakyol AH. Hepatitis B Virus Reactivation under Treatment with Nilotinib. Euroasian J Hepato-Gastroenterol 2015;5(2

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

280. Propylthiouracil-related Toxic Hepatitis: Impact of Silent Cases

Propylthiouracil-related Toxic Hepatitis: Impact of Silent Cases 29201711 2018 11 13 2231-5047 5 2 2015 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Propylthiouracil-related Toxic Hepatitis: Impact of Silent Cases. 134-135 10.5005/jp-journals-10018-1153 Liver is the main organ which can metabolize many drugs or chemical agents. Toxic events developed by drugs are one of the most common causes of liver damage. Toxic hepatitis can be encountered (...) in different clinical situations, such as acute hepatitis, fulminant hepatitis chronic hepatitis or cirrhosis. We aimed to report a case of asymptomatic toxic hepatitis in a patient taking propylthiouracil (PTU). A 38 years old female patient admitted to hospital complained of fatigue. She had no special medical history except Graves' disease. She had been taking PTU 300 mg/day for 1 month. She had no history of another medication, eating mushroom, alcohol consumption, traveling, family history of liver

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro